228 related articles for article (PubMed ID: 24215532)
1. Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders.
Pathak S; Roth M; Verma A; Steidl U
Expert Opin Drug Metab Toxicol; 2013 Dec; 9(12):1667-75. PubMed ID: 24215532
[TBL] [Abstract][Full Text] [Related]
2. Thrombopoietin mimetics for patients with myelodysplastic syndromes.
Dodillet H; Kreuzer KA; Monsef I; Skoetz N
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD009883. PubMed ID: 28962071
[TBL] [Abstract][Full Text] [Related]
3. Effect of the nonpeptide thrombopoietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome.
Will B; Kawahara M; Luciano JP; Bruns I; Parekh S; Erickson-Miller CL; Aivado MA; Verma A; Steidl U
Blood; 2009 Oct; 114(18):3899-908. PubMed ID: 19710504
[TBL] [Abstract][Full Text] [Related]
4. Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.
Mittelman M; Platzbecker U; Afanasyev B; Grosicki S; Wong RSM; Anagnostopoulos A; Brenner B; Denzlinger C; Rossi G; Nagler A; Garcia-Delgado R; Portella MSO; Zhu Z; Selleslag D
Lancet Haematol; 2018 Jan; 5(1):e34-e43. PubMed ID: 29241762
[TBL] [Abstract][Full Text] [Related]
5. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
Platzbecker U; Wong RS; Verma A; Abboud C; Araujo S; Chiou TJ; Feigert J; Yeh SP; Götze K; Gorin NC; Greenberg P; Kambhampati S; Kim YJ; Lee JH; Lyons R; Ruggeri M; Santini V; Cheng G; Jang JH; Chen CY; Johnson B; Bennett J; Mannino F; Kamel YM; Stone N; Dougherty S; Chan G; Giagounidis A
Lancet Haematol; 2015 Oct; 2(10):e417-26. PubMed ID: 26686043
[TBL] [Abstract][Full Text] [Related]
6. The new thrombopoietic agenda: impact on leukemias and MDS.
Bussel JB
Best Pract Res Clin Haematol; 2014; 27(3-4):288-92. PubMed ID: 25455280
[TBL] [Abstract][Full Text] [Related]
7. Eltrombopag for treatment of thrombocytopenia-associated disorders.
Merli P; Strocchio L; Vinti L; Palumbo G; Locatelli F
Expert Opin Pharmacother; 2015; 16(14):2243-56. PubMed ID: 26364898
[TBL] [Abstract][Full Text] [Related]
8. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial.
Oliva EN; Alati C; Santini V; Poloni A; Molteni A; Niscola P; Salvi F; Sanpaolo G; Balleari E; Germing U; Fenaux P; Stamatoullas A; Palumbo GA; Salutari P; Impera S; Avanzini P; Cortelezzi A; Liberati AM; Carluccio P; Buccisano F; Voso MT; Mancini S; Kulasekararaj A; Morabito F; Bocchia M; Cufari P; Spiriti MA; Santacaterina I; D'Errigo MG; Bova I; Zini G; Latagliata R
Lancet Haematol; 2017 Mar; 4(3):e127-e136. PubMed ID: 28162984
[TBL] [Abstract][Full Text] [Related]
9. Eltrombopag for the treatment of immune thrombocytopenia.
Cheng G
Expert Rev Hematol; 2011 Jun; 4(3):261-9. PubMed ID: 21671710
[TBL] [Abstract][Full Text] [Related]
10. Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.
Kühne T; Imbach P
Ann Hematol; 2010 Jul; 89 Suppl 1():67-74. PubMed ID: 20405290
[TBL] [Abstract][Full Text] [Related]
11. Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies.
Li W; Morrone K; Kambhampati S; Will B; Steidl U; Verma A
Leukemia; 2016 Mar; 30(3):536-44. PubMed ID: 26500138
[TBL] [Abstract][Full Text] [Related]
12. Current status of thrombopoietic agents.
Rhodes E; Stasi R
Expert Rev Hematol; 2010 Apr; 3(2):217-25. PubMed ID: 21083464
[TBL] [Abstract][Full Text] [Related]
13. Eltrombopag in chronic hepatitis C.
Mihăilă RG; Cipăian RC
World J Gastroenterol; 2014 Sep; 20(35):12517-21. PubMed ID: 25253952
[TBL] [Abstract][Full Text] [Related]
14. Eltrombopag in Immune Thrombocytopenia, Aplastic Anemia, and Myelodysplastic Syndrome: From Megakaryopoiesis to Immunomodulation.
Fattizzo B; Levati G; Cassin R; Barcellini W
Drugs; 2019 Aug; 79(12):1305-1319. PubMed ID: 31292909
[TBL] [Abstract][Full Text] [Related]
15. Eltrombopag for myelodysplastic syndromes or chronic myelomonocytic leukaemia with no excess blasts and thrombocytopenia: a French multicentre retrospective real-life study.
Comont T; Meunier M; Cherait A; Santana C; Cluzeau T; Slama B; Laribi K; Giraud JT; Dimicoli S; Berceanu A; Le Clech L; Cony-Makhoul P; Gruson B; Torregrosa J; Sanhes L; Jachiet V; Azerad MA; Al Jijakli A; Gyan E; Gaudin C; Broner J; Guerveno C; Guillaume T; Ades PL; Beyne-Rauzy O; Fenaux P;
Br J Haematol; 2021 Jul; 194(2):336-343. PubMed ID: 34151423
[TBL] [Abstract][Full Text] [Related]
16. Eltrombopag (Promacta), a thrombopoietin receptor agonist for the treatment of thrombocytopenia: current and future considerations.
Serebruany VL; Eisert C; Sabaeva E; Makarov L
Am J Ther; 2010; 17(1):68-74. PubMed ID: 19451811
[TBL] [Abstract][Full Text] [Related]
17. Eltrombopag in chronic idiopathic thrombocytopenic purpura and HCV-related thrombocytopenia.
Panzer S
Drugs Today (Barc); 2009 Feb; 45(2):93-9. PubMed ID: 19343229
[TBL] [Abstract][Full Text] [Related]
18. Use of eltrombopag for the treatment of thrombocytopenia in hypoplastic myelodysplastic syndrome.
Gauchan D; Shaaban H; Gedeon D; Maroules M
Ann Hematol; 2014 Oct; 93(10):1777-8. PubMed ID: 24554304
[No Abstract] [Full Text] [Related]
19. A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.
Svensson T; Chowdhury O; Garelius H; Lorenz F; Saft L; Jacobsen SE; Hellström-Lindberg E; Cherif H
Eur J Haematol; 2014 Nov; 93(5):439-45. PubMed ID: 24853277
[TBL] [Abstract][Full Text] [Related]
20. Use of eltrombopag, a thrombopoietin receptor agonist, in post-transplantation thrombocytopenia.
Reid R; Bennett JM; Becker M; Chen Y; Milner L; Phillips GL; Liesveld J
Am J Hematol; 2012 Jul; 87(7):743-5. PubMed ID: 22573520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]